Showing results (1151-1160 of 1,243) with videos related to
Sort By:
Pageof 125
Journal of the American College of Cardiology|August 27, 2023
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal FunctionSafia Chatur, Muthiah Vaduganathan, Brian L Claggett, et al.Journal of the American College of Cardiology|August 23, 2023
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart FailureToru Kondo, Xiaowen Wang, Mingming Yang, et al.Journal of the American College of Cardiology|December 16, 2022
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection FractionMikhail N Kosiborod, Ankeet S Bhatt, Brian L Claggett, et al.EFSA Journal. European Food Safety Authority|July 7, 2020
Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms, Colin Ockleford, Paulien Adriaanse, et al.The American Journal of Cardiology|April 26, 2016
Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial)Marco Metra, Robert J Mentz, Adrian F Hernandez, et al.EFSA Journal. European Food Safety Authority|September 3, 2020
Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on the genotoxic potential of triazine amine (metabolite common to several sulfonylurea active substances), Antonio F Hernandez-Jerez, Paulien Adriaanse, et al.Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.Journal of Participatory Medicine|March 29, 2021
Data Sharing Goals for Nonprofit Funders of Clinical TrialsTimothy Coetzee, Mad Price Ball, Marc Boutin, et al.JAMA Cardiology|May 20, 2023
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER TrialAlexander Peikert, Alvin Chandra, Mikhail N Kosiborod, et al.Circulation|March 6, 2023
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER TrialToru Kondo, Karola S Jering, C Jan Willem Borleffs, et al.Pageof 125